German China
Search

UK: Nanofibre Technology GE Healthcare Acquires Producer of Nanofibers

| Editor: Alexander Stark

GE Healthcare has completed the acquisition of Puridify, a bioprocessing start-up that is developing a nanofiber-based platform purification technology for biopharmaceutical production. Puridify’s technology, Fibro Select, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing.

Related Company

Puridify’s technology, Fibro Select, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing,
Puridify’s technology, Fibro Select, is complementary to the bead resins and chromatography membranes used today in downstream bioprocessing,
(Source: GE Healthcare)

Chalfont St Giles/UK — The company has collaborated with several major biopharmaceutical manufacturers in the development of their technology. The platform is expected to bring productivity improvements in the process development (PD) phase and small-scale manufacturing for a wide variety of biopharmaceutical applications. GE Healthcare will invest further to bring the platform to commercialization fully integrating it within the broad range of bioprocess purification products already available at GE.

GE will acquire Puridify and all 17 employees will join GE Healthcare Life Sciences’ Bio Process business. The Puridify team will remain at their current location in Stevenage, UK, which will serve as a small research hub for Bio Process. Since it was founded in 2014 and after winning the first One Start competition, Puridify has been privately funded by leading venture capital investors Touchstone Innovations and SR One, with additional support from University College London (UCL) Business.

“The technology that Puridify has been developing gives GE access to exciting technology that could give considerable improvements for some customers in their purification step. The early feedback from collaborators has been positive. Today’s investment in this new technology is further evidence of GE’s strong commitment to innovation in the production of biopharmaceuticals to the benefit of our customers and of patients world-wide,” said Jan Makela, General Manager, Bio Process, GE Healthcare Life Sciences.

(ID:45032617)